Aldeyra Therapeutics, Inc. (ALDX)
NASDAQ: ALDX · Real-Time Price · USD
5.02
-0.28 (-5.28%)
At close: Nov 13, 2025, 4:00 PM EST
5.01
-0.01 (-0.20%)
Pre-market: Nov 14, 2025, 6:46 AM EST
Aldeyra Therapeutics Employees
Aldeyra Therapeutics had 9 employees as of December 31, 2024. The number of employees decreased by 1 or -10.00% compared to the previous year.
Employees
9
Change (1Y)
-1
Growth (1Y)
-10.00%
Revenue / Employee
n/a
Profits / Employee
-$4,799,325
Market Cap
302.02M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9 | -1 | -10.00% |
| Dec 31, 2023 | 10 | -5 | -33.33% |
| Dec 31, 2022 | 15 | 3 | 25.00% |
| Dec 31, 2021 | 12 | 1 | 9.09% |
| Dec 31, 2020 | 11 | -9 | -45.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ALDX News
- 16 hours ago - Aldeyra Therapeutics, Inc. (ALDX) Discusses Expansion of RASP Platform Into CNS Diseases and Update on Reproxalap for Dry Eye Transcript - Seeking Alpha
- 1 day ago - Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast - Business Wire
- 3 days ago - Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London - Business Wire
- 8 days ago - Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET - Business Wire
- 17 days ago - Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules - Business Wire
- 5 weeks ago - 4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals - Benzinga
- 2 months ago - Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - Business Wire
- 2 months ago - Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma - Business Wire